Nov 20, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Wall Street Analysts Think Ocular Therapeutix ( OCUL ) Could Surge 82.48%: Read This Before Placing a Bet
The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nov 12, 2025 • Benzinga
NEUTRAL
Ocular Therapeutix™ to Participate in November and December Investor Conferences - Ocular Therapeutix ( NASDAQ:OCUL )
BEDFORD, Mass., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ:OCUL, "Ocular" ) ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025.
Nov 07, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BEDFORD, Mass., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Ocular Therapeutix, Inc. ( NASDAQ: OCUL, "Ocular" ) , an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired non-executive employee.
Nov 04, 2025 • Zacks Commentary
NEUTRAL
Ocular Therapeutix ( OCUL ) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +5.13% and +8.89%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 04, 2025 • GlobeNewswire
NEUTRAL
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...
Nov 04, 2025 • Benzinga
SOMEWHAT-BULLISH
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R - Ocular Therapeutix ( NASDAQ:OCUL )
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD